UK markets closed

MorphoSys AG (MOR.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
67.750.00 (0.00%)
At close: 05:36PM CEST
Full screen
Previous close67.75
Open67.75
Bid67.75 x 1500
Ask67.80 x 8800
Day's range67.75 - 67.80
52-week range14.52 - 69.75
Volume18,531
Avg. volume108,580
Market cap2.552B
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-5.53
Earnings date07 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est54.50
  • Business Wire

    MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

    PLANEGG/MUNICH, Germany, July 12, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act").

  • Business Wire

    MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders

    PLANEGG/MUNICH, Germany, June 20, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squ

  • Zacks

    Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

    Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.